Lübeck/New Delhi, 13 October 2008; After the successful introduction of products and services across the European region new business links are now being established in India. India is a country with one of the highest growth potentials in the world. Increasingly more pharmaceutical companies carry out clinical studies in India and more and more Indian companies enter the European and American market in order to obtain authorization for their medicines and to market them there. In line with this trend the management of Amedon GmbH has been conducting various talks in India for the last few months and has been looking for a suitable partner as well as new clients. In the course of these talks further interesting business fields in telemedicine and emergency medical services could be identified. The existing system solutions of AMEDON GmbH were able to convince its clients and arouse their interest. On 13 October 2008, Mr Vinay Rathee and...

XClinical executives will showcase the company’s innovations regarding products and services. Dr. Claus Lindenau will hold a lecture in the session “CDISC SDTM Data Conversion”. XClinical GmbH, Munich, Germany – June 17, 2008 – XClinical, a European vendor of innovative software products for e-clinical trials, and known for its innovative CDISC certified EDC software suite MARVIN, today announced its participation at the 44th Annual DIA Meeting to be held on June 22 to 26, 2008, in Boston, MA, USA. “The forthcoming DIA event will welcome attendees from all geographic locations, making it the perfect venue for global networking opportunities”, said Dr. Lindenau, XClinical’s head of business development. After XClinical’s successful expansion into the U.S. market last year, the company’s next step is now to further strengthen its presence in the United States. BioStat International Inc. (BSI), XClinical’s recent U.S. client,...

One of XClinical’s customers, the Munich-based CRO OSE Oncology Services Europe S.a.r.l., has just started a large clinical trial for one of Europe’s premier pharmaceutical companies. XCLINICAL GMBH, Munich, Germany – May 14, 2008 – XClinical, a European vendor of innovative software products for eClinical trials, announced the use of MARVIN, its CDISC ODM certified EDC solution, in a large European multicentric clinical trial conducted by its Munich-based customer, OSE Oncology Services Europe S.a.r.l. (OSE). The study, initiated by the subsidiary of a global pharmaceutical company, will take place in 20 countries and involves up to 160 sites. OSE, who has only recently joined XClinical’s growing customer list, and was trained on MARVIN in a very short time, is responsible for the project. MARVIN’s special ability to combine EDC (Electronic Data Capture) and DDE (Double Data Entry) was the key feature in being chosen for the mentioned...

XClinical’s CEO, Dr. Philippe Verplancke, has been selected to speak at the CDISC European Interchange in Copenhagen in April 2008 where he will discuss the challenges of combining user-friendliness and CDISC data standards in an EDC system. XClinical is furthermore contributing to the CDISC End-to-End Workshop (“CORE”). Dr. Verplancke has recently been invited to perform the official ODM/define.xml trainings and will be an official guest speaker at CDISC road shows and user-group meetings in 2008. XCLINICAL GMBH, Munich, Germany – April 9, 2008 – XClinical, a European vendor of innovative software products for eClinical...

XClinical GmbH, Munich, Germany – March 10, 2008 – XClinical, a European vendor of innovative software products for e-clinical trials, today reported that BioStat International Inc. (BSI), a contract research organization (CRO) headquartered in Tampa, FL, USA, will soon begin a very unique medical device study. BSI was trained at the end of October 2007 on behalf of a global industry leader. The comprehensive training session on MARVIN, XClinical’s innovative EDC system, empowered the CRO in less than 12 weeks to set-up the clinical trial independently without the assistance of XClinical’s technical personnel. The ability to...